重庆智飞生物制品股份有限公司独立董事 关于第五届董事会第十一次会议相关事项的独立意见 我们作为重庆智飞生物制品股份有限公司（以下简称"公司"）的独立董事, 参加了2023年8月25日公司召开的第五届董事会第十一次会议，根据《上市公司 独立董事规则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市 公司自律监管指引第2号——创业板上市公司规范运作》等有关法律、法规、规 范性文件以及《公司章程》的规定，本着谨慎、实事求是的原则和对公司及全体 股东负责的态度，我们对控股股东及其他关联方占用公司资金情况、公司对外担 保情况等事项进行了审核，并就各事项发表如下的独立意见： 一、关于控股股东及其他关联方占用公司资金情况的意见 报告期内，公司未发生任何形式的对外重大担保事项,也没有以前期间发生 并延续到报告期的对外担保事项。 三、关于公司关联交易事项的意见 报告期内，公司发生的关联交易决策程序符合有关法律、法规、规范性文件 及《公司章程》的规定，定价原则合理、公允，未发生重大关联交易事项,亦不 存在与关联方发生重大关联交易的情况，不存在损害公司和所有股东利益的行为。 独立董事：袁林、陈煦江、龚涛 2023 年 8 ...

2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 上市公司名称：重庆智飞生物制品股份有限公司 单位：万元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司 | 上市公司核算 | 2023 年期初占 | 2023 年 用累计发生金额 | 1-6 月占 | 2023 年 1-6 用资金的利息 | 月占 | 2023 年 1-6 | 月偿 | 2023 年 6 月末 | | 占用 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 的关联关系 | 的会计科目 | 用资金余额 | | | | | 还累计发生金额 | | 占用资金余额 | | 形成原因 | | | | | | | | （不含利息） | | (如有） | | | | | | | | | 现大股东 | | | | | | | | | | | | | | | | 及其附属企业 | | | | | | | | | | | | | | | | 小计 | | | | | | | ...

证券代码：300122 证券简称：智飞生物 公告编号：2023-38 重庆智飞生物制品股份有限公司 第五届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、本次监事会于 2023 年 8 月 15 日以电子邮件的方式向监事发出通知。 5、本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件和公司章程的规定。 二、监事会会议审议情况 经过认真审议，本次会议形成了如下决议： 1、审议通过了《2023 年半年度报告》及《2023 年半年度报告摘要》 经审核，监事会认为：董事会编制和审核公司 2023 年半年度报告及摘要的 程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反 映了公司的实际经营情况，不存在任何虚假记载、误导性陈述或重大遗漏。 《2023 年半年度报告》及《2023 年半年度报告摘要》于同日发布于中国证 监会指定的创业板上市公司信息披露网站巨潮资讯网。 表决结果：赞成 3 票，反对 0 票，弃权 0 票，本议案获得通过。 2、本次会议于 2023 年 8 月 ...

证券代码：300122 证券简称：智飞生物 公告编号：2023-35 重庆智飞生物制品股份有限公司 关于卡介菌纯蛋白衍生物（BCG-PPD）进入 II 期临床试验的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆智飞生物制品股份有限公司（以下简称"公司"）近日获悉由全资子公 司安徽智飞龙科马生物制药有限公司自主研发的卡介菌纯蛋白衍生物（BCG-PPD） 在深圳市第三人民医院开展 II 期临床试验。 三、风险提示 1、药品研制是非常复杂严谨的科学活动，具有投入大，周期长，风险高的 特点，产品的研发和行政审批主要有以下几个阶段：临床前研究；申请临床试 验；进行临床试验；申请生产文号；上市销售。 1 一、项目简介 卡介菌纯蛋白衍生物（BCG-PPD）是公司开发的全新工艺产品。该产品的结 核菌素皮肤试验（TST）可用于结核病的辅助诊断、结核病流行病学调查及卡介 苗（BCG）接种后机体免疫反应的监测。 截至本公告披露日，经查询国家药品监督管理局网站，国内共有两款卡介菌 纯蛋白衍生物产品获批上市。 二、II 期临床试验相关情况 卡介菌纯蛋白衍生物（BCG-PPD ...

Financial Performance - The company's revenue for Q1 2023 reached ¥11,172,773,125.45, representing a 26.37% increase compared to ¥8,841,150,250.19 in the same period last year[4] - Net profit attributable to shareholders was ¥2,032,024,553.16, a 5.68% increase from ¥1,922,756,886.80 year-on-year[4] - Basic earnings per share for Q1 2023 was ¥1.2700, reflecting a 5.68% increase from ¥1.2017 in the same quarter last year[4] - Total operating revenue for Q1 2023 reached CNY 11,172,773,125.45, a significant increase from CNY 8,841,150,250.19 in Q1 2022, representing a growth of approximately 26.9%[19] - Net profit for Q1 2023 was CNY 2,032,024,553.16, compared to CNY 1,922,756,886.80 in the same period last year, reflecting an increase of about 5.7%[20] - The company reported a total comprehensive income of CNY 2,032,024,553.16 for Q1 2023, compared to CNY 1,922,756,886.80 in the same period last year, showing an increase of about 5.7%[21] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, with a net outflow of ¥1,040,028,831.23, a 68.64% reduction from the previous year's outflow of ¥3,316,743,954.40[11] - The company reported a significant increase in cash and cash equivalents of ¥176,160,972.80, a 107.60% improvement compared to a significant decrease in the previous year[11] - The cash inflow from financing activities totaled 2,866,915,531.74 CNY, an increase from 1,720,866,416.95 CNY in the prior period[24] - The net cash flow from financing activities was 1,491,721,904.16 CNY, compared to 1,412,329,711.67 CNY in the previous period[24] - The cash and cash equivalents at the end of the period amounted to 2,791,849,824.14 CNY, up from 1,961,452,199.09 CNY in the prior period[24] - The company experienced a net increase in cash and cash equivalents of 176,160,972.80 CNY, contrasting with a decrease of -2,318,248,546.21 CNY in the previous period[24] Assets and Liabilities - Total assets increased by 13.78% to ¥43,242,428,755.31 from ¥38,003,733,941.95 at the end of the previous year[5] - The total assets of the company increased to CNY 43,242,428,755.31 from CNY 38,003,733,941.95 at the beginning of the year, marking a growth of about 13.5%[18] - Total current liabilities increased to CNY 16.36 billion from CNY 13.23 billion, which is an increase of approximately 23.8%[17] - The company's total liabilities reached CNY 16.97 billion, compared to CNY 13.77 billion at the beginning of the year, indicating a growth of approximately 23.9%[17] Research and Development - The company's R&D expenses rose to ¥213,960,021.59, marking a 32.98% increase compared to ¥160,890,893.91 in the prior year[10] - Research and development expenses amounted to CNY 213,960,021.59, up from CNY 160,890,893.91 in Q1 2022, indicating a year-over-year increase of approximately 33%[20] Equity and Shareholder Information - The total equity attributable to shareholders increased by 8.38% to ¥26,268,237,162.33 from ¥24,236,212,609.17 at the end of the previous year[5] - The company's total equity attributable to shareholders reached CNY 26,268,237,162.33, up from CNY 24,236,212,609.17 at the beginning of the year, indicating a growth of approximately 8.4%[18] Employee Compensation and Engagement - The company reported a significant increase in employee compensation liabilities, which decreased to CNY 36.53 million from CNY 182.21 million, indicating a reduction of approximately 80%[17] - The company is actively involved in employee stock ownership plans, with specific funds allocated for this purpose, indicating a strategic focus on employee engagement and retention[14] Other Financial Metrics - The weighted average return on equity decreased to 8.05%, down by 2.28% from 10.33% in the same period last year[4] - Tax expenses for Q1 2023 were CNY 360,264,719.19, slightly higher than CNY 340,224,600.65 in Q1 2022, reflecting an increase of approximately 5.9%[20] - The total operating costs for Q1 2023 were CNY 8,596,876,197.85, up from CNY 6,503,327,142.16 in the same period last year, reflecting an increase of about 32.4%[19] Audit Status - The first quarter report was not audited[25]

Financial Performance - In 2022, the company's revenue exceeded 38.2 billion CNY, and net profit surpassed 7.5 billion CNY, demonstrating significant growth in performance[2]. - Chongqing Zhifei Biological Products Co., Ltd. reported a total revenue of RMB 3.5 billion in 2022, representing a year-on-year increase of 15%[18]. - The company achieved a net profit of RMB 1.2 billion, with a profit margin of approximately 34%[18]. - The company's operating revenue for 2022 was approximately ¥38.26 billion, representing a 24.83% increase from ¥30.65 billion in 2021[22]. - The net profit attributable to shareholders for 2022 was approximately ¥7.54 billion, a decrease of 26.15% compared to ¥10.21 billion in 2021[22]. - The net cash flow from operating activities for 2022 was approximately ¥1.99 billion, down 76.62% from ¥8.51 billion in 2021[22]. - The total assets at the end of 2022 were approximately ¥38.00 billion, an increase of 26.48% from ¥30.05 billion at the end of 2021[22]. - The company's basic earnings per share for 2022 were ¥4.71, down 26.15% from ¥6.38 in 2021[22]. - The company reported a net profit of approximately ¥29.10 million from non-recurring gains and losses in 2022, compared to ¥24.41 million in 2021[27]. - The company reported a sound financial condition with a well-established financial system and accurate financial reports reflecting the 2022 operating results[141]. Research and Development - The company has established three major R&D bases in Beijing, Anhui, and Chongqing, with nine R&D technology platforms and eight product matrices, showcasing its comprehensive capability from R&D to industrialization[2]. - The company has successfully launched seven self-developed products, including the world's first approved recombinant COVID-19 protein vaccine, highlighting its innovation strength[2]. - The company aims to enhance its R&D capabilities by focusing on independent research and development, with plans to launch important products like PCV15 and MCV4 vaccines[7]. - The company has established a clinical research team of over 100 members to enhance the speed of clinical research projects, aiming for timely product launches to benefit the public[10]. - The company has 28 projects in its research pipeline, with 16 projects already in the registration process, enhancing its core competitiveness[42]. - The company is actively involved in the development of mRNA technology through its investment in a biotechnology platform[34]. - The company is advancing multiple vaccine research projects, including a broad-spectrum COVID-19 vaccine based on mRNA technology[57]. - The company has obtained a total of 42 patents to date, indicating a strong focus on intellectual property management[45]. - The company has launched the second-generation COVID-19 vaccine (Omicron-Delta chimeric vaccine) international clinical trial in Uzbekistan[57]. Market Expansion and Strategy - The global human vaccine market is projected to grow from approximately 27.7 billion USD in 2017 to about 46 billion USD in 2021, with expectations to reach around 131 billion USD by 2030[4]. - The Chinese vaccine market is expected to exceed 340 billion CNY by 2030, driven by increasing health awareness and government policies supporting the pharmaceutical industry[4]. - The company plans to expand its market presence by launching three new vaccine products in 2023, targeting both domestic and international markets[18]. - The company aims to achieve a revenue growth target of 10% for 2023, driven by new product launches and market expansion strategies[18]. - The company is focusing on international team building to improve overseas registration, product certification, and commercial promotion capabilities, leveraging successful experiences from its COVID-19 vaccine WHO-EUL certification[10]. - The company is committed to contributing to the Healthy China strategy and supporting national development goals through its growth and innovation efforts[10]. - The company is actively pursuing international partnerships and product registration to enhance vaccine accessibility and equity[64]. Quality and Compliance - The company has a production qualification rate of 100% and has received EU QP certification and WHO-EUL verification for its COVID-19 vaccine, indicating high-quality standards[4]. - The company emphasizes compliance with national regulations in the production and distribution of vaccines, ensuring quality management throughout the production process[39]. - The company maintains a 100% pass rate for product batch release since 2008, ensuring high-quality standards[52]. - The company is committed to optimizing the management of early-stage research, clinical studies, and drug registration processes to expedite the launch of high-quality products[10]. - The company targets a 100% qualification rate for product quality management, adhering strictly to laws and industry standards[96]. Corporate Governance and Management - The company has established a comprehensive quality management system covering all stages from R&D to sales[52]. - The company adheres to strict governance structures, with a board of directors comprising 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[108]. - The company has a clear policy for remuneration that aligns with its operational performance and strategic goals[128]. - The company has a structured compensation decision-making process based on profitability and individual performance[128]. - The company has established a talent management strategy to cultivate a skilled workforce in the biopharmaceutical sector, focusing on fair and diverse recruitment policies[99]. - The company has a well-defined governance structure, including independent shareholder meetings and boards[113]. - The company has not faced any penalties from securities regulatory agencies in the past three years[127]. Environmental Responsibility - The company adheres to environmental protection laws and regulations, fulfilling its ecological responsibilities[164]. - The company has implemented a green and sustainable development strategy in its operations[164]. - The company has established pollution discharge standards, including a limit of 0.6 mg/L for total phosphorus, which is part of the compliance measures[172]. - The company has implemented a comprehensive pollution monitoring system, ensuring compliance with environmental regulations and standards[177]. - The company has established an emergency response plan for environmental incidents and conducts regular drills to enhance response capabilities[176]. - The company achieved 100% compliance in waste disposal, preventing environmental pollution[175]. Employee Engagement and Culture - The company has implemented a comprehensive employee training system focusing on cultural, professional, and leadership training[147]. - The company emphasizes a performance-based compensation system to motivate employees and align their interests with the company's growth[145]. - The company has established an employee stock ownership plan involving 1,923 core employees, with a total of 29,100,000 shares held, accounting for 1.82% of the total share capital[154]. - The company has a total of 1,210 production staff, 3,359 sales personnel, and 807 technical staff, reflecting a diverse professional composition[144]. - The workforce increased by 935 employees, a growth rate of 19.48%, bringing the total to 5,735 employees[53].

证券代码：300122 证券简称：智飞生物 公告编号：2023-15 重庆智飞生物制品股份有限公司 关于举行2022年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 2023 年 3 月 21 日 1 重庆智飞生物制品股份有限公司（以下简称"公司"）《2022年年度报告》 已于2023年3月21日公布于中国证监会指定信息披露网站巨潮资讯网。为进一步 解读公司年度报告，帮助广大投资者更深入全面地了解公司经营情况，公司定于 2023年4月6日（星期四）15:00-17:00在全景网举行2022年度业绩网上说明会。 本次年度业绩说明会将采用网络远程的方式举行，投资者可登陆"全景路演" （http://rs.p5w.net）参与会议，与公司管理层互动、沟通。 出席本次年度业绩说明会的人员情况如下：董事长兼总裁蒋仁生先生、董 事会秘书秦菲先生、财务总监李振敬先生、独立董事袁林女士。 为充分尊重投资者，广泛听取投资者的意见和建议，现就公司2022年度业绩 说明会提前向投资者公开征集问题，提问通道自发出公告之日起开放。投资者可 于2023年4月6日（ ...